CCL3 and rheumatoid arthritis: In patients with RA, MIP-1A triggers signaling pathways by binding to receptors on the surface of chondrocytes, leading to altered activation of intracellular molecules and inhibition of proteoglycan synthesis, ultimately affecting chondrocyte function (65, 66).